MARKET

AGTC

AGTC

AGTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.740
+0.060
+1.28%
Pre Market: 4.850 +0.11 +2.32% 08:48 01/25 EST
OPEN
4.660
PREV CLOSE
4.680
HIGH
4.760
LOW
4.600
VOLUME
30
TURNOVER
--
52 WEEK HIGH
8.45
52 WEEK LOW
2.290
MARKET CAP
122.72M
P/E (TTM)
-2.2201
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference
GlobeNewswire · 01/06 21:01
AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President & Chief Execut...
GlobeNewswire · 01/06 21:01
Is AGTC A Good Stock To Buy Now?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in re...
Insider Monkey · 12/11/2020 20:05
Why Applied Genetic Technologies' (NASDAQ:AGTC) CEO Pay Matters
This article will reflect on the compensation paid to Sue Washer who has served as CEO of Applied Genetic Technologies...
Simply Wall St. · 12/11/2020 04:33
These 2 “Strong Buy” Penny Stocks Could Go Boom, Says Roth Capital
TipRanks · 12/01/2020 16:35
These 2 Strong Buy Penny Stocks Could Go Boom, Says Roth Capital
What kind of stocks stir up controversy like no other? Penny stocks. These tickers trading for less than $5 per share have earned a reputation as some of the most divisive names on Wall Street, with these plays either met with open arms or given the cold s...
TipRanks · 12/01/2020 16:35
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Misses Revenue Estimates
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -17.65% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/16/2020 22:35
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Misses Revenue Estimates
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -17.65% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/16/2020 22:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGTC. Analyze the recent business situations of AGTC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGTC stock price target is 14.81 with a high estimate of 30.00 and a low estimate of 7.50.
EPS
Institutional Holdings
Institutions: 104
Institutional Holdings: 16.31M
% Owned: 63.00%
Shares Outstanding: 25.89M
TypeInstitutionsShares
Increased
18
983.52K
New
21
-365.53K
Decreased
26
1.65M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Independent Director
Scott Koenig
President/Chief Executive Officer/Director
Susan Washer
Chief Financial Officer
William Sullivan
Executive Vice President
Matthew Feinsod
Chief Scientific Officer
Mark Shearman
Vice President
Stephen Potter
Independent Director
William Aliski
Independent Director
Edward Hurwitz
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
James Rosen
Independent Director
Anne VanLent
Director
Ivana Magovcevic
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AGTC
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
More

Webull offers kinds of Applied Genetic Technologies Corp stock information, including NASDAQ:AGTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGTC stock methods without spending real money on the virtual paper trading platform.